Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

CONCLUSIONS: Ribociclib plus fulvestrant demonstrated safety in the treatment of patients with HR+, HER2- ABC. Triple combinations with alpelisib or buparlisib plus fulvestrant are not recommended for phase II investigation. NCT02088684.
PMID: 32887722 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 3, 2020 Category: Cancer & Oncology Authors: Tolaney SM, Im YH, Calvo E, Lu YS, Hamilton EP, Forero-Torres A, Bachelot T, Maur M, Fasolo A, Tiedt R, Nardi L, Stammberger U, Abdelhady AM, Ruan S, Lee SC Tags: Clin Cancer Res Source Type: research